ENGLISH  |  FRANÇAIS  |  日本語  |  中文  |  PRESS ROOM  |  CONTACT US  | 

Firm Overview

Smart & Biggar is Canada's largest firm practising exclusively in intellectual property and technology law, with offices in Ottawa,
Toronto, Montreal, and Vancouver. Since our inception over a century ago, we have been dedicated to one purpose: delivering unparalleled IP.

>> more

Rankings and Recognitions

We are committed to providing our clients with the highest quality service and advice and we are proud that our services are consistently recognized in surveys of Canadian and international intellectual property practitioners.

>> more

Firm History

The collaboration of Smart & Biggar/Fetherstonhaugh laid the foundation for delivering unparalleled IP service and solutions over a century ago.

>> more

Practice Areas
Our team advises clients on a wide variety of existing and emerging IP and technology matters.   Click on any of the links below to learn more about a particular practice.
Legal Services
 Industry Specializations

 

Professionals
Search by typing professional's last name or with any combination of name, keyword, or other criteria.

 
   
   

Offices
With offices across the country and a network that spans the globe, we offer our clients strategic counsel and an efficient gateway to the world.

For more information, please select an office below:

Ottawa | Toronto | Montreal | Vancouver

Articles
Our professionals regularly report on new developments in all areas of intellectual property and technology law. Please click here to view our list of articles.
Newsletters
IP Perspectives

Rx IP Update

IP Connections

Canadian ReMARKS

Subscribe
Media
Coming soon
In order to better assist our clients and contacts, we are pleased to provide general information on Canadian intellectual property policies and proceduress, as well information on filing in certain foreign jurisdictions.

 

Careers
Smart & Biggar offers a variety of challenging and rewarding positions for professionals, students and administrative staff. Please select the appropriate link below to learn more about current opportunities.

Students | Professional | Administrative
Professionals

Gunars A. Gaikis
Partner, Toronto
Barrister and Solicitor,
Patent and Trade-mark Agent

 

CONTACT
Phone: 416.593.5514
Fax: 416.591.1690
YEAR OF CALL
Ontario Bar 1983
QUALIFICATIONS
  • University of Toronto B.Sc.Phm. (Pharmacy) 1977
  • Residency in Hospital Pharmacy 1978
  • Osgoode Hall Law School of York University J.D. 1981
  • Registered Trade-mark Agent 1983
  • Registered Patent Agent 1987
  • Registered to practise before the United States Patent and Trademark Office
 

Gunars Gaikis has specialized in pharmaceutical and biological patent litigation and strategic advising for over 20 years. He has extensive experience in procurement, litigation and resolution of disputes relating to pharmaceutical and biotechnology patents and has appeared as lead counsel in numerous intellectual property cases before the Ontario, Federal and Supreme courts.

Mr. Gaikis primarily acts on behalf of patentees in the innovative pharmaceutical industry. As a licensed pharmacist and having completed a residency program in clinical pharmacy, Mr. Gaikis is very familiar with medical and pharmaceutical matters, including the relevant regulatory issues. This background coupled with his in-depth expertise in complex pharmaceutical and biotechnology patent litigation make Mr. Gaikis an invaluable asset to clients operating in these fields.


Rankings and recognition

  • Selected to appear in Benchmark Litigation Canada 2012
  • Selected to appear in IAM Patent Litigation 250 — The World's Leading Patent Litigators
  • Listed in The Best Lawyers in Canada under Biotechnology Law and Intellectual Property Law
  • Recognized in Chambers Global 2012 – The World’s Leading Lawyers for Business under Intellectual Property: Litigation
  • Recognized in The Canadian Legal LEXPERT® Directory under Intellectual Property and Litigation — Intellectual Property
  • Selected to appear in The LEXPERT®/American Lawyer Guide to the Leading 500 Lawyers in Canada under Intellectual Property and Intellectual Property Litigation
  • Selected to appear in the LEXPERT® Guide to the Leading US/Canada Cross-Border Litigation Lawyers in Canada under Intellectual Property Litigation
  • Recognized in IAM Life Sciences 250 – The World’s Leading Life Sciences Patent Litigators 2010
  • Selected to appear in The International Who's Who of Life Sciences Lawyers
  • Listed in The International Who's Who of Patent Lawyers
  • Listed in Life Sciences Specialist 500
  • Selected for inclusion in PLC Which Lawyer? under IP: patent litigation and Life sciences: patent litigation
  • Listed in Who's Who Legal: Canada 2011 under Life Sciences and Patents
PRACTICE AREAS
Pharmaceutical
Litigation
Patents
Life Sciences
Trade-marks
Chemical
IP Management & Strategic Counselling
Licensing & IP Transactions
Pharmaceutical Regulatory & Compliance
 
LANGUAGES SPOKEN
English
Latvian
 

Proceedings under the Patented Medicines (Notice of Compliance) Regulations

Aventis-Pharma Inc. v. Pharmascience Inc., 2009 FC 915 (ramipril)

AstraZeneca Canada Inc. v. Apotex Inc., 2008 FC 1316 (esomeprazole)

sanofi-aventis Canada Inc. v. Laboratoire Riva Inc., 2008 FC 291 (ramipril)

sanofi-aventis Canada Inc. v. Canada (Health), 2008 FC 129 (ramipril)

sanofi-aventis Canada Ltd. v. Laboratoire Riva Inc., 2007 FC 1317 (ramipril)

sanofi-aventis Canada Inc. v. Pharmascience Inc., 2007 FC 1057 (ramipril)

sanofi-aventis Inc. v. Laboratoire Riva Inc., 2007 FC 532 (ramipril)

AB Hassle v. Apotex Inc., 2008 FC 184 (omeprazole)

sanofi-aventis Canada Inc. v. Novopharm Limited, 2006 FC 1547 (ramipril)

sanofi-aventis Canada Inc. v. Novopharm Limited, 2006 FC 1473 (ramipril)

AstraZeneca AB v. Apotex Inc., 2006 FC 7 (omeprazole)

Aventis Pharma Inc. v. Apotex Inc., 2005 FC 1504 (ramipril)

Aventis Pharma Inc. v. Apotex Inc., 2005 FC 1461 (ramipril)

Aventis Pharma Inc. v. Apotex Inc., 2005 FC 1381 (ramipril)

Aventis Pharma Inc. v. Apotex Inc., 2005 FC 1283 (ramipril)

AstraZeneca Canada Inc. v. Apotex Inc., 2005 FCA 216 (omeprazole)

Aventis Pharma Inc. v. Pharmascience Inc., 2005 FC 340 (ramipril)

AB Hassle v. Apotex Inc., 2005 FC 234 (omeprazole)

AstraZeneca AB v. Apotex Inc., 2004 FC 71 (omeprazole)

AB Hassle v. Genpharm Inc., 2003 FC 1443 (omeprazole)

AB Hassle v. Apotex Inc., 2003 FC 903 (omeprazole)

AB Hassle v. Apotex Inc., 2003 FCT 771 (omeprazole)

AstraZeneca Canada Inc. v. Apotex Inc., 2002 FCT 1250 (omeprazole)

Wyeth-Ayerst Canada Inc. v. Faulding Canada Inc., 2002 FCT 969 (piperacillin)

AB Hassle v. Apotex Inc., 2002 FCT 931 (omeprazole)

AB Hassle v. Rhoxalpharma Inc., 2002 FCT 780 (omeprazole)

Rhoxalpharma Inc. v. AB Hassle, 2002 FCA 147 (omeprazole)

Hassle v. Apotex Inc., 2002 FCT 222 (omeprazole)

Hassle v. Canada (Minister of National Health and Welfare), 2001 FCT 1264 (omeprazole)

AB Hassle v. Canada (Minister of National Health and Welfare), 9 C.P.R. (4th) 79 (omeprazole)

Merck Frosst Canada Inc. v. Canada (Minister of Health), 8 C.P.R. (4th) 87 (timolol)

AB Hassle v. Canada (Minister of National Health and Welfare) 190 F.T.R. 264 (omeprazole)

Bayer AG v. Canada (Minister of National Health and Welfare), 77 C.P.R. (3d) 129 (ciprofloxacin)

Hoffmann-La Roche Limited v. Apotex Inc., 72 C.P.R. (3d) 480 (ketorolac)

AB Hassle v. Canada (Minister of National Health and Welfare), 72 C.P.R. (3d) 318 (metoprolol)

Pharmacia Inc. v. Ben Venue Laboratories Inc., 72 C.P.R. (3d) 229 (doxorubicin)

 


Interim/interlocutory injunctions

 Aventis Pharma S.A. v. Novopharm Ltd., 2005 FC 815 (enoxaparin)

 

Zeneca Ltd. v. Apotex Inc. (1997), 79 C.P.R. (3d) 399 (Ont. Ct. Gen. Div.) (lisinopril)

Ciba-Geigy Canada Ltd. v. Novopharm Ltd. (1994), 56 C.P.R. (3d) 289 (F.C.T.D.) (diclofenac)

Ciba-Geigy Canada Ltd. v. Novopharm Ltd. (1993), 52 C.P.R. (3d) 497 (F.C.T.D.) (diclofenac)

Sklar-Peppler Inc. v. Decor-Rest Furniture Ltd. (1990), 34 C.P.R. (3d) 76 (F.C.T.D.) (industrial design, sofa)

 


Pharmaceutical patent infringement/validity/section 8 actions

 

 

sanofi-aventis canada Inc. v. Apotex Inc.; sanofi-aventis Canada Inc. v. Novopharm Inc., 2009 FC 676 (ramipril)

Apotex Inc. v. Syntex Pharmaceuticals International Ltd. and Hoffmann LaRoche Limited, 2009 FC 494 (naproxen)

Merck & Co. Inc. v. Apotex Inc., 2006 FC 524 (lisinopril)

Apotex Inc. v. Syntex Pharmaceuticals International Ltd., 1 C.P.R. (4th) 22 (naproxen)


Judicial review

Bayer Schering Pharma Aktiengesellschaft v. Canada (Attorney General), 2009 FC 1249 (patent claims)

Bayer Inc. v. Canada (Health), 2009 FC 1171 (estradiol)

sanofi-aventis Canada Inc. v. Canada (Health), 2009 FCA 169 (ramipril)

Bayer Inc. v. Canada (Health), 2009 FCA 133 (estradiol)

Immunex Corporation v. Canada (Health), 2008 FC 1409 (etanercept)

sanofi-aventis Canada Inc. v. Canada (Health), 2008 FC 1062 (ramipril)

Bayer Inc. v. Canada (Health), 2008 FC 857 (estradiol)

Ferring Inc. v. Canada (Health), 2007 FCA 276 (ramipril)

Ferring Inc. v. Canada (Health), 2007 FC 300 (ramipril)

sanofi-aventis Canada Inc. v. Canada (Minister of Health), 2006 FC 1559 (ramipril)

Hoffmann-La Roche Ltd. v. Canada (Minister of Health), 2004 FC 1547 (trastuzumab)

AstraZeneca Canada Inc. v. Canada (Minister of Health), 2004 FC 1278 (omeprazole)

AstraZeneca Canada Inc. v. Canada (Minister of Health), 2004 FC 1277 (omeprazole)


Appeals

Federal Court of Appeal

Apotex Inc. v. AB Hassle, 2008 FCA 416 (omeprazole)

Hässle v. Apotex Inc., 2008 FCA 88 (omeprazole)

Novopharm Limited v. sanofi-aventis Canada Inc., 2007 FCA 167 (ramipril)

Apotex Inc. v. sanofi-aventis Canada Inc., 2007 FCA 7 (ramipril)

sanofi-aventis Canada Inc. v. Apotex Inc., 2006 FCA 357 (ramipril)

sanofi-aventis Canada Inc. v. Apotex Inc., 2006 FCA 328 (ramipril)

Apotex Inc. v. Merck & Co., 2006 FCA 323 (lisinopril)

Apotex Inc. v. Merck & Co., 2006 FCA 324 (lisinopril)

Apotex Inc. v. Merck & Co. Inc., 2006 FCA 198 (lisinopril)

Aventis Pharma Inc. v. Apotex Inc., 2006 FCA 64 (ramipril)

AstraZeneca Canada Inc. v. Canada (Minister of Health), 2005 FCA 208 (omeprazole)

AstraZeneca Canada Inc. v. Canada (Minister of Health), 2005 FCA 189 (omeprazole)

AstraZeneca AB v. Apotex Inc.?, 2005 FCA 183 (omeprazole)

Hoffman-La Roche Ltd. v. Canada (Minister of Health), 2005 FCA 140 (trastuzumab)

Merck & Co. Inc. v. Apotex Inc., 2003 FCA 488 (lisinopril)

Apotex Inc. v. AB Hassle, 2003 FCA 409 (omeprazole)

Apotex Inc. v. AB Hassle, 2003 FCA 87 (omeprazole)

AstraZeneca AB v. Novopharm Ltd., 2003 FCA 57 (felodipine)

AB Hassle v. Canada (Minister of National Health and Welfare), 2002 FCA 421 (omeprazole)

Novopharm Ltd. v. AstraZeneca AB, 2002 FCA 387 (felodipine)

Hoffmann-La Roche v. Canada (Minister of National Health and Welfare), 9 C.P.R. (4th) 90; aff'd 85 C.P.R. (3d) 67 (flunisolide)

Supreme Court of Canada

AstraZeneca Canada Inc. v. Canada (Minister of Health), 2006 SCC 49 (omeprazole)

Memberships

  • Fellow, Intellectual Property Institute of Canada
  • Member, Pharmaceutical Trade Marks Group
  • Member, American Intellectual Property Law Association
  • Member, Canadian Bar Association; past long-time Chair of the Patent Committee of the Intellectual Property Section


Speaking engagements

  • "Damages in Patent Infringement and Section 8 Cases: The View from Both Sides" panel discussion at the Canadian Institute's 10th Annual Forum on Pharma Patents, Toronto, October 2011
  • "Strategies in Pharma Patent Litigation," Insight Information's 9th conference on Drug Patents in Canada, Toronto, May 2010
  • "Pharma Patents Litigation: Year in Review," panel discussion at The Canadian Institute's 8th Annual Forum on Pharma Patents, Toronto, October 2009
  • "Pharma Patent Trials Within Two Years," Insight Information's Drug Patent and Legal Forum, Toronto, May 2009
  • "Year in Review – Regulatory Developments" (co-presenters: Nancy P. Pei and Daphne C. Lainson) and "Year in Review – Litigation" (co-presenters: J. Sheldon Hamilton and Yoon Kang), Smart & Biggar’s Pharma Patents 2008, Mississauga, ON, November 2008
  • "Pharma Patents and Competition Law Issues: Patentee’s Perspective," Insight Information’s Drug Patents and Legal Forum, Toronto, February 2008
  • "Successfully Maximizing Product Life Cycle: What Every Innovator Needs to Know," "The Canadian Institute's National Business and Legal Guide to Life Sciences Business and Legal, Ottawa, April 2008
  • "Pharma Patents – The Year in Review" (co-presenters: J. Sheldon Hamilton, Yoon Kang, Nancy P. Pei and Denise L. Lacombe) and "Pharmaceutical Product Life Cycle Management – Patents and the Regulatory Environment, Including Data Protection and the Patented Medicines (Notice of Compliance) Regulations" (co-presenter: Nancy P. Pei), Smart & Biggar’s Pharma Patents 2007, Mississauga, ON, November 2007
  • "Authorized Generics and Relevant Licensing Issues," The Canadian Institute's 6th Annual Forum on Pharma Patents, Toronto, October 2007
  • "Changes to Patented Medicines (NOC) Regulations — Industry Perspective" (co-presenter: Nancy P. Pei), Canadian Association of Professional Regulatory Affairs symposium From Product Monograph to Promotion and Other Emerging Initiatives, Toronto, November 2007
  • "Successfully Protecting Exclusivity in the New Regulatory Framework," The Canadian Institute's Summit on Pharmaceutical & Biotech Regulatory Compliance, Toronto, March 2007
  • "Preventing, Defending, and Financing IP Litigation," Insight/ALM conference Intellectual Property: Building, Protecting, and Profiting From Your IP Portfolio, Toronto, November 2006
  • "Pharma Patents and the Regulatory Environment" (co-presenter: Nancy P. Pei), "Litigating Pharma Patents" (co-presenters: John R. Morrissey and Steven B. Garland) and “Hot Topics and Discussion" (co-presenters: A. David Morrow and J. Sheldon Hamilton), Smart & Biggar's Pharma Patents 2006, Mississauga, ON, November 2006

Publications

  • "The Patentability of Pharmaceutical Dosage Regimes in Canada" (co-author: David E. Schwartz), 26 Canadian Intellectual Property Review 2, December 2010
  • "Pharmaceutical Patent Litigation is Inevitable — Typically Overlooked Licensing Terms" (co-authors: Junyi Chen, Jeff J. Kang and Rebecca B. Rodal), presented at the Federated Press conference titled "Negotiating & Drafting Bio Pharma Contracts," June 2011
  • "Minimizing the Risk of Section 8 Damages" (co-authors: Andrew Mandlsohn, Patrick M. Roszell and Alain Laplume), presented at the 9th Annual Forum on Pharma Patents, November 2010
  • "Analyzing the Latest Developments in the Law to Identify Emerging Trends, Opportunities and Threats" (co-authors: Andrew Mandlsohn, Urszula Wojtyra and Jordan D. Scopa), presented at the 8th Annual Forum on Pharma Patents, October 2009
  • "Understanding Key Issues Impacting the Industry Today: Recent Developments in the Law of Patents" (co-authors: Andrew Mandlsohn and Jayda A. Sutton), presented at the 7th Annual Forum on Pharma Patents, October 2008
  • "Unique IP Issues in Canada's Pharmaceutical and Biotechnology Industry" (co-authors: Daphne C. Lainson and David E. Schwartz), The 2006 LEXPERT Guide to the Top 100 Industry Specialists in Canada, October 2006, pp. 125-129
  • "Proposed Amendments to the Patented Medicines (Notice of Compliance) Regulations and Data Protection Provisions of the Food and Drug Regulations" (co-author: Junyi Chen), presented at the Canadian Institute’s Pharmaceutical & Biotech Regulatory Compliance Conference, March 2006
  • "Recent Jurisprudence Under the NOC Regulations" (co-author: Junyi Chen ), presented at the Canadian Institute’s 4th Annual Forum on Pharma Patents: The Legal and Strategic Guide, October 2005
  • "Listing Patents on the Patent Register" (co-author: Junyi Chen), presented at Drug Patents: The Latest Legal, Regulatory, and Litigation Developments, March 2005
?